Framingham, United States
RootPath, founded in 2017, is a pioneering entity in the Biotechnology sector, headquartered in the United States. The company's slogan, "Enabling biology at scale," encapsulates its mission to revolutionize gene function interrogation through its proprietary molecular programming-based DNA fragment assembly technology.
RootPath's innovative platform significantly enhances the ability of life science researchers, drug developers, and synthetic biologists to access precise, long synthetic genes and their functional readouts, thus advancing the field of synthetic biology.
In its most recent funding round on 07 September 2021, RootPath secured a $50.00M Series B investment. The round was supported by prominent investors including Sky9 Capital, CDH Investments, Matrix Partners China, and Hony Capital. This investment underscores strong confidence in RootPath's capability to deliver scalable biological solutions and its potential to drive transformative impacts within the industry.
